Massive kidney trial aims to revolutionize how we test treatments
NCT ID NCT07595952
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
APT-KIDNEY is a large, flexible clinical trial platform designed to test multiple treatments for advanced kidney disease more efficiently. It will enroll up to 5,000 adults with severe kidney problems or those on dialysis. By using electronic health records and adaptive methods, the platform aims to produce faster, more practical evidence to improve care.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- What this could lead to
- If successful, this platform could speed up testing of many kidney disease treatments, leading to faster, more reliable answers about what works.
- What could go wrong
- This is a trial framework, not a single treatment test. It hasn't started recruiting yet, and its success depends on many future domain-specific trials.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHRONIC KIDNEY DISEASE (STAGES 4 AND 5) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Could your bone health decide if a dental implant lasts?
- Can new antibodies make dialysis safer by preventing clots without bleeding?
- Can a simple foot pump ease leg swelling in hospital patients?
- Could your blood type predict kidney treatment success?
- Can community hospitals in zambia master severe disease care?
- Can an ancient herbal remedy soothe the aftermath of stone surgery?